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Background: Despite widespread guidelines recommending the use of lung-protective ventilation
(LPV) in patients with acute lung injury (ALI), many patients do not receive this lifesaving
therapy. We sought to estimate the incremental clinical and economic outcomes associated with
LPV and determined the maximum cost of a hypothetical intervention to improve adherence with
LPV that remained cost-effective.
Methods: Adopting a societal perspective, we developed a theoretical decision model to deter-
mine the cost-effectiveness of LPV compared to non-LPV care. Model inputs were derived from
the literature and a large population-based cohort of patients with ALI. Cost-effectiveness was
determined as the cost per life saved and the cost per quality-adjusted life-years (QALYs) gained.
Results: Application of LPV resulted in an increase in QALYs gained by 15% (4.21 years for
non-LPV vs 4.83 years for LPV), and an increase in lifetime costs of $7,233 per patient with ALI
($99,588 for non-LPV vs $106,821 for LPV). The incremental cost-effectiveness ratios for LPV
were $22,566 per life saved at hospital discharge and $11,690 per QALY gained. The maximum,
cost-effective, per patient investment in a hypothetical program to improve LPV adherence from
50 to 90% was $9,482. Results were robust to a wide range of economic and patient parameter
assumptions.
Conclusions: Even a costly intervention to improve adherence with low-tidal volume ventilation
in patients with ALI reduces death and is cost-effective by current societal standards.
(CHEST 2009; 136:79–88)
Abbreviations: ALI  acute lung injury; ICER  incremental cost-effectiveness ratio; KCLIP  King County Lung
Injury Project; LPV  lung-protective ventilation; PCEHM  Panel on Cost Effectiveness in Health and Medicine;
QALY  quality-adjusted life-year
A
cute lung injury (ALI) is responsible for up to
75,000 deaths in the United States each year.1 To
date, only one therapy has proven beneficial in
reducing the mortality of ALI, namely, protocol-
based delivery of pressure-limited, low-tidal volume
ventilation (ie, lung-protective ventilation [LPV]).2,3
Based on this evidence, many persons in the critical
care community4,5 have called for the use of LPV in
all patients with ALI. Although ventilator practice
has changed since the publication of the landmark
randomized trial demonstrating the efficacy of LPV,
a large proportion of patients with ALI still receive
mechanical ventilation with tidal volumes above the
goal of 6 mL/kg predicted body weight.4,6–14 Barriers
to the delivery of LPV include concern about adverse
effects of low tidal volumes, inadequate knowledge
of the LPV protocol, underrecognition of ALI, and
an unwillingness of the bedside physician to relin-
quish control of the ventilator.6,10,13
Despite an increased awareness of the barriers to
LPV delivery, ongoing investigation into improving
adherence with this therapy is lacking.15,16 Many of
the barriers to LPV adherence could theoretically be
overcome by implementing a multidisciplinary ap-
proach, including protocolized screening and care,
bedside decision support, education of existing staff,
and audit and feedback.16 Yet, these approaches
carry costs that must be weighed against the clinical
benefits of LPV. The objective of this analysis was
to determine the cost-effectiveness of LPV and to
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intervention aimed at improving ICU-level LPV
adherence remains cost-effective. Given the clinical
benefits of LPV in patients with ALI, we hypothe-
sized that even a costly intervention that increased
LPV utilization would be cost-effective by current
societal standards.
Materials and Methods
The study was approved by the Institutional Review Board of
the University of Washington. Our goal was to determine the
cost-effectiveness of LPV and the clinical and economic conse-
quences of an intervention to improve adherence with LPV in
ALI patients from the societal perspective. Currently, to our
knowledge, there are no large multicenter studies evaluating the
effectiveness of an intervention to improve adherence with
LPV.16 In the absence of evidence, we chose to model the
cost-effectiveness of LPV by itself, recognizing that even an
intervention with zero up-front costs has important downstream
costs. We then estimated the maximum cost for a hypothetical
ICU-level intervention aimed at improving LPV adherence, thus
exploring the cost-effectiveness of LPV implementation under a
worst-cost scenario.
We generated a decision model comparing the ventilatory care
of the ALI patient with and without use of an LPV protocol
(Fig 1). Our model included a decision node for a hypothetical
intervention aimed at improving LPV adherence at the ICU level.
We then performed the following two analyses: a base-case
analysis (Fig 1, box), evaluating the cost-effectiveness of LPV as
the sole intervention; and an intervention-case analysis evaluating
the influence of an intervention aimed at improving the adher-
ence with LPV. As recommended by the Panel on Cost Effec-
tiveness in Health and Medicine (PCEHM), we applied a
lifetime time horizon in the analysis.17
Effects
We measured incremental effect as the number of life-years
gained and number of quality-adjusted life-years (QALYs) gained
between the non-LPV and the LPV arms of the decision model.17
We modeled QALYs as previously described in critically ill
populations with and without ALI.18,19 The age of each hospital
survivor was estimated from the King County Lung Injury
Project (KCLIP), a population-based study of the incidence and
outcomes of ALI.1 We calculated the number of life-years by
determining the age-matched mean life expectancy for each
hospital survivor by ALI risk factor in our population using the
2004 life tables from the National Center for Health Statistics.20
This life expectancy was further discounted by the expected
reduction in life expectancy experienced by survivors of sepsis
(51% reduction in long-term survival) and for nonsepsis survivors
of ALI (10% reduction in long-term survival).21,22 To generate
QALYs, we multiplied the mean adjusted life expectancy by the
mean Quality of Well-Being scale for 1-year survivors of ALI
(0.60),23 as recommended by the PCEHM for the calculation of
QALYs.17
Costs and Resource Use
For the base case, we determined the difference in costs
between the LPV arm and the non-LPV arm of the decision
model, obtaining estimates of the costs for each day spent in the
hospital (ie, in the ICU, receiving ventilation, or on the ward)
from the medical literature (Table 1).24,25 Because LPV does not
affect the need for additional supportive therapies, including
vasopressors, IV fluids, or diuretics, or the need for sedation and
neuromuscular blockade, no other costs due to LPV were
included in this analysis.26,27 Posthospitalization costs for the first
2 years after hospital discharge were estimated from the litera-
ture and updated to 2008 US dollars.28 For survival beyond the
first 2 years, costs were calculated using age-specific medical
expenditure data from the Statistical Abstract of the United
States and the Bureau of Labor Statistics for 2006.29,30 We
assigned each hospital survivor the average posthospital expen-
ditures of someone in the general population with the same life
expectancy rather than the same age. This approach, used by
other cost-effectiveness analyses in critical illness, assigns greater
medical expenditures to survivors of ALI than those incurred by
an age-matched general population because it assigns health-care
costs based on the reduced life expectancy associated with
survival after ALI. These costs include subsequent hospitaliza-
tions, outpatient care, rehabilitation costs, and home care costs.
Annual costs were updated monthly for each year of survival for
each patient until death using a time-dependent Markov model
(Fig 1, Markov tree).
For the intervention case, we used the decision model to
determine the maximum cost for an ICU-wide intervention that
would remain cost-effective at the $50,000 per QALY gained
threshold. ICUs were assumed to care for an average of 40 cases
of ALI per year, which was estimated from KCLIP.
Likelihood of Events
Table 2 lists the probabilities of clinical events used in the
decision model. We assumed that the relative risk reduction for
application of the LPV protocol would mimic the results of the
landmark clinical trial as well as a metaanalysis.2,3 For the
intervention-case analysis, the proportion of patients who receive
LPV in the usual-care arm were estimated from the medical
literature.4,6–13 We assumed that a hypothetical intervention
would improve adherence with LPV from a baseline value of 50%
up to 90%.
Statistical Analysis
We performed a series of one-way and multi-way sensitivity
analyses to evaluate the uncertainty in the decision model,
varying all model inputs according to their specified ranges.
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incremental cost-effectiveness ratio (ICER) for the base-case
model were plotted in a tornado diagram. To explore the
relationships among the baseline rate of LPV adherence, interven-
tion cost, and postintervention LPV adherence in the intervention-
case analysis, we varied these three parameters in a three-way
sensitivity analysis. The impact of the uncertainty in all of the
parameters simultaneously was ascertained by performing a
multivariate sensitivity analysis using Monte Carlo simulation.
Each parameter in the model was assigned a distribution that
closely fit the mean of the parameter and its uncertainty.31 Ten
thousand patients were simulated, and the ICER was calculated
for each simulation. We identified the central region containing
95% of the estimates for the ICER.
Analyses were conducted using appropriate software (TreeAge
Pro 2008; TreeAge Software; Williamstown, MA). All costs were
converted to 2008 US dollars by using the gross domestic product
deflator.32 Both costs and effects were discounted at a 3% annual
rate as recommended by the PCEHM.17,33
Results
Base-Case Analysis
The lifetime cost of care for a patient with ALI
receiving LPV was $106,821 compared to $99,588
for non-LPV ALI care, for a difference in cost of
$7,233. The hospital mortality rate in the LPV arm
was 31% compared to 40% in the non-LPV arm,
resulting in a number of patients-needed-to-treat
with LPV to save one life of 11. The discounted,
age-adjusted average life expectancy for a hospital
survivor with sepsis was 6.5 years, for a hospital
survivor with trauma 13.4 years, and for patients
without either trauma or sepsis 7.0 years. Patients
receiving LPV had an average of 4.83 QALYs after
hospital discharge; non-LPV care resulted in 4.21
QALYs. When short-term and long-term costs and
utilities were combined, the incremental cost-
effectiveness for the base case was $11,690 per
QALY. This number reflects the cost of each
QALY gained by delivering LPV to a patient with
ALI. On combining costs and lives saved at hospi-
tal discharge, the incremental cost-effectiveness
for LPV in the base case was $22,566 per life
saved.
Intervention-Case Analysis
Assuming an ICU-wide intervention could im-
prove LPV adherence from a baseline of 50 to 90%
in an ICU caring for 40 patients with ALI per year,
an intervention costing a maximum of $379,284
remained cost-effective. This value indicates that
investing up to $9,482 in a single patient to ensure
that the chances of that patient receiving LPV
improve from 50 to 90% is a cost-effective strategy.
Figure 1. Simplified schema of the decision model. From left to right, the square node represents the
decision to implement an intervention to improve LPV adherence. The hollow circular nodes are
“chance nodes,” representing the downstream consequences of the decision. The triangular nodes at
the end of each pathway represent the cumulative costs and effects of each pathway. The circular nodes
with a central “M” represent a patient surviving hospitalization and entering into a time-dependent
Markov process (separate subtree). The subtree outlined by the dashed line was used for the base-case
analysis. The actual tree used in the model incorporates risk factor (sepsis, trauma, other).
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Figure 2 shows the impact of the most influen-
tial individual parameters on the ICER for the
base-case analysis. The ICER generated by the
model was most sensitive to variability in the total
number of ventilated days for patients with sepsis
and the life expectancy of survivors with ALI due
to sepsis. However, LPV remained cost-effective
relative to non-LPV care over all ranges for each
variable in the analysis.
Table 2—Parameters Used in the Cost-effectiveness Model
Parameter or Probability Base-Case Value (Range) Intervention-Case Value (Range) Reference
Hospital volume of ALI patients/yr 40 (20–100) 1
Risk factor for ALI 1,47
Sepsis 72% (50–80) 72% (50–80)
Trauma 7% (5–14) 7% (5–14)
Other 21% (6–45) 21% (6–45)
LPV protocol implementation
Probability (LPV implemented/usual care) 0 (0–0) 0.50 (0.2–0.80) 6–14
Probability (LPV implemented/intervention) 1.0 (1.0–1.0) 0.90 (0.85–1.0)
Mortality
Relative risk of death (LPV) 0.78 (0.65–0.93) 0.78 (0.65–0.93) 2,3,48
Probability (death/no LPV) 0.4 (0.35–0.45) 0.4 (0.35–0.45) 2,3,48
Probability (death/LPV)* 0.31 (0.23–0.42) 0.31 (0.23–0.42) 2,3,48
Utility
ALI survival 0.60 (0.4–1.0) 0.60 (0.4–1.0) 23
Death 0 0
*Probability of death given by LPV, calculated by multiplying the relative risk of death for LPV by the probability of death for patients ventilated
without LPV.
Table 1—Assumptions, Sources, and Values for Costs Used in Analysis
Costs Survivors Nonsurvivors All Notes, Assumptions, and Sources
Duration of each type of hospital day, d LOS data were derived from the
KCLIP
1; costs for each arm in the
model were calculated by multiplying
the cost for each different type of day
by the LOS associated with that day;
base-case values were varied by  2
SDs in two-way sensitivity analyses*
Ventilated ICU days (both arms)
Sepsis 7.9 (10.7) 6.7 (8.5)
Trauma 9.9 (7.5) 5.7 (6.6)
Other 6.1 (10.4) 8.5 (12.6)
Nonventilated ICU days (both arms)
Sepsis 3.4 (5.1) 1.1 (3.1)
Trauma 2.4 (3.6) 0.8 (1.9)
Other 3.2 (4.2) 1.2 (4.4)
Ward days (both arms)
Sepsis 7.5 (9.5) 1.5 (5.8)
Trauma 10.3 (11.2) 1.7 (5.6)
Other 8.6 (14.9) 1.9 (5.4)
Cost for each type of day, $US Estimates reflect average daily costs of
mechanically ventilated patients,
nonventilated ICU patients, and a
50% reduction in cost associated with
transfer to the floor
24,25
Ventilated ICU day 5,232 (1,000–8,000)
Nonventilated ICU day 3,563 (1,000–5,000)
Ward day 1,782 (500–3,000)
Posthospital medical costs
First year 11,311 (5,000–22,000) Incorporate all posthospitalization costs
(subsequent hospitalizations,
outpatient visits, rehabilitation, home
care)
28
Second year 8,448 (4,000–17,000)
Beyond second year (age-specific) ( 25%)† Health-care expenditures based on the
Statistical Abstract of the United
States and the Bureau of Labor
Statistics for 2006
29,30
Death, $US 6,676 (5,007–8,346) One-time cost at time of death; this cost
approximates the societal cost for care
associated with a fatal illness
45,46
Values are given as mean (SD) or mean (range). LOS  length of stay.
*Assumes that LPV does not result in differences in length of stay other than that resulting from lower mortality.
†Adjusted age-specific health-care costs.
82 Original ResearchProbability-based sensitivity analyses for the base
case indicated that most simulations were cost-
effective according to standard thresholds (Fig 3). Of
the 10,000 simulations, 84% had ICERs  $20,000
per QALY, 98.9% had ICERs  $50,000 per QALY,
and 99.6% had ICERs  $100,000 per QALY.
Figure 4 shows a three-way sensitivity analysis for
the intervention-case analysis. The maximal cost-
effective per patient investment depended on the
baseline rate of LPV adherence in an ICU and the
projected rate of adherence postintervention. ICUs
with lower rates of LPV delivery have much higher
maximum intervention costs per patient, which re-
main cost-effective. However, a large per patient
monetary investment aimed at improving the prob-
ability of LPV delivery remained cost-effective re-
gardless of the baseline rates of LPV delivery. For
example, ICUs interested in improving their LPV
adherence from a baseline of 70 to 85% of patients
could invest up to $3,556 per patient with ALI into
an ICU-wide intervention to achieve this improved
adherence. Interventions costing  $3,556 per pa-
tient in this particular ICU would cause the inter-
vention to have an ICER of  $50,000 per QALY.
Investing up to $7,112 per patient to achieve 100%
adherence in the same ICU would remain cost-
effective.
Discussion
We utilized decision analysis techniques to model
the clinical and economic outcomes associated with
LPV and to determine the maximum cost of an
intervention aimed at improving LPV delivery that
remained cost-effective. The results of the analysis
indicate that low-tidal volume ventilation is a highly
cost-effective strategy. These findings were robust to
an extensive sensitivity analysis. Based on current
societal cost-effectiveness standards, we determined
that the average ICU should be willing to spend up
to $9,500 per patient with ALI to ensure that the
patient receives LPV.
The United States spends more on health care
than any other country, yet our health outcomes are
consistently below average.33 This discrepancy may
in part result from misplaced priorities of health-care
spending.34 Each year, the National Institutes of
Health allocates the majority of its research budget
to basic science and the development of new treat-
ments, yet  1% of its budget is directed toward
ensuring that patients receive such treatments.34,35
As a result, many well-known cost-effective therapies
are not delivered to the patients who could directly
benefit. Instead, billions of dollars are spent on tests
and treatments that lack evidence of effective-
Figure 2. Tornado diagram. The effect of individual variables on the cost-effectiveness of LPV. Bars
indicate how the cost-effectiveness of LPV vs no LPV changes when parameters are varied in one-way
sensitivity analyses from the lowest to the highest extreme of their plausible range (extreme values are
shown adjacent to bars). The base-case line represents the incremental cost-effectiveness calculated for
the base case.
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In fact, a large proportion of these expenditures are
attributable to care delivered in an ICU.36
In an effort to address these issues, policy experts
have called for34,35 a fundamental reordering of
health priorities toward therapies known to be cost-
effective. Although a necessary first step, prioritizing
cost-effective therapies may not lead to improved
health unless there is a concomitant effort to im-
prove adherence to such therapies. To date, there
has been minimal national effort to study and
implement mechanisms to improve adherence to
evidence-based practice in the ICU. More often,
such investigation is initiated under local quality
improvement efforts. Until we know exactly which
therapies in the ICU are cost-effective and how to
improve adherence to these therapies, the onus of
providing care that is both evidence based and value
based lies in the hands of the hospital, ICU, and
individual providers.37
Our results have significant implications for ICUs
and critical care providers who care for patients with
ALI. Through implementing LPV, ICUs and critical
care providers have the ability to decrease mortality
and, as a result, increase the QALYs for their patients
with ALI. Importantly, our model indicates that LPV
can be provided at a lower cost than other commonly
used ICU interventions (Table 3).
How can hospitals, ICU directors, and critical care
providers use the results of our analysis? We chose to
evaluate the maximum cost of a hypothetical ICU-
based intervention to improve LPV adherence that
would remain cost-effective, allowing us to deter-
mine intervention cost under a hypothetical “most
expensive” scenario. Despite evidence that many
patients do not currently receive LPV,4,6–12 some
ICUs may implement this protocol in a higher
proportion of patients, yet even these ICUs can
improve their adherence to 100% in a cost-effective
way. Using data from Figure 4, even an excellent
ICU with baseline LPV adherence of 80% could
spend as much as $4,750 per patient to achieve 100%
adherence and, if our analysis is correct, still be
within the standard criteria of cost-effectiveness.
Therefore, in a typical 15-bed medical-surgical ICU
that cares for 30 to 60 ALI patients per year,38 a
Figure 3. Probability-based sensitivity analysis. For each one of the 10,000 trials, values for the
parameters in the model are selected from their respective distributions and an ICER is calculated. A
95% confidence ellipse is placed around 95% of the points and represents the uncertainty in the ICER
estimate. Points falling above the dotted line have an ICER of  $50,000 per QALY; those falling below
the line have ICERs of  $50,000 per QALY. A random 2,000 of 10,000 points are represented.
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costing $140,000 to $280,000 per year would be
cost-effective. These data can be used to justify
quality improvement programs in critical care and
will allow hospitals, ICU directors, and critical care
providers to assess their need for interventions to
improve adherence to LPV based on their local
practice.
It is important to note that our cost-effectiveness
estimates and the estimated maximum interventional
cost that remains cost-effective are likely conserva-
tive. First, most hospital costs incurred by LPV result
from the prolonged hospital stay for patients who
survive ALI. We utilized estimates for the cost of
hospital days that were based on average daily costs
from the literature. Increasing length of stay, how-
ever, only incurs marginal costs, or the cost of each
additional ICU day, rather than average costs.39
Average costs are much higher because they include
the first few days of ICU care, which typically are
much costlier than subsequent days. The incorpora-
tion of marginal costs into our model would have




Early goal-directed therapy in sepsis Huang et al
19/2007 Early goal-directed therapy in septic patients vs usual care 7,400
LPV Low-tidal volume ventilation vs usual care in ALI patients 11,690
Drotrecogin alfa (activated) Fowler et al
49/2003 Severe sepsis with APACHE score  24 vs standard therapy 15,100
Angus et al
18/2003 Severe sepsis with APACHE score  24 vs standard therapy 31,300
ICD Owens et al
50/1997 ICD only (40% mortality reduction) vs amiodarone 46,000
Lung transplantation Ramsey et al
51/1995 ICD only vs standard care, assuming 10-yr survival 230,000
Cardiopulmonary resuscitation Lee et al
52/1996 In-hospital care vs none 280,000
The cost-effectiveness of LPV seems comparable to that of early goal-directed therapy for sepsis and is superior to the cost-effectiveness of therapy
with activated protein C, ICDs, lung transplantation, and cardiopulmonary resuscitation. APACHE  acute physiology and chronic health
evaluation; ICD  internal cardiac defibrillator.
*Cost inflated to 2008 US dollars.
Figure 4. Three-way sensitivity analysis. The diagonal black lines represent the maximum per-patient
intervention cost remaining cost-effective over the range of baseline LPV adherence rates for each
postintervention adherence rate. For a given postintervention LPV adherence, all shaded areas falling
below its diagonal line are cost-effective (ICER  $50,000 per QALY). All areas falling above the
diagonal line are not cost-effective (ICER  $50,000 per QALY). The dotted lines provide examples
of the cost required to improve LPV adherence from 70 to 85% or to 100%.
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maximum per patient investment to improve LPV
adherence. Second, we considered an ICER of
 $50,000 per QALY as indicative that the intervention
remained cost-effective. Many widely adopted critical
care therapies, however, have ICERs that exceed this
threshold (Table 3). Utilizing a QALY threshold that is
more consistent with the societal value of health care
($200,000 per QALY)40 would result in a much greater
maximum, cost-effective cost for a hypothetical inter-
vention to improve LPV adherence.
We were unable to populate our model with an
actual intervention targeting LPV adherence be-
cause, to date and to our knowledge, no large-scale,
community-based programs to improve the quality
of care to mechanically ventilated patients exist.16
There are, however, multiple theoretical interven-
tions that a hospital could implement to improve
LPV delivery. Higher intensity ICU staffing such as
hiring 24-h intensivists may result in improved ad-
herence to LPV.41 Alternatively, hiring additional
respiratory therapy staff dedicated to identifying ALI
and implementing LPV may also result in greater
adherence. Other interventions, such as the auto-
mated identification of ALI patients; auditing and
feedback of LPV adherence data; using provider-
specific adherence rates for pay-for-performance
initiatives, computerized reminders, or decision sup-
port; and structured interactive education of staff all
have the potential to improve adherence with LPV,
yet none have been rigorously tested in this patient
population.42 Critical care investigators should test
such interventions to determine whether they suc-
cessfully improve LPV adherence rates and can be
generalized to the broader community. Hospitals
with smaller ICUs that do not have protocols for
patients with ALI can invest money to develop
ventilator protocols that implement low-tidal volume
ventilation. Given the lack of evidence for ways to
improve ventilatory practice, hospital and ICU poli-
cymakers can tailor their investment toward inter-
ventions that have the most local support.
We recognize a number of limitations to our
analysis. First, estimates of the efficacy of LPV
primarily derive from a single study conducted by
the ARDS Network 2000.2 Although estimates were
corroborated with a metaanalysis,4 pooled estimates
of the relative risk reduction in mortality associated
with LPV are largely driven by the ARDS Network
study.2 Moreover, mortality rates and the relative
efficacy of LPV may have changed as ICU care has
improved over time.43 Second, we utilized the largest
currently available, population-based sample of pa-
tients with ALI in the United States to derive
estimates of length of stay for survivors and nonsur-
vivors. Accurate estimates of length of hospital stay
for ALI patients were important because hospital
expenses are primarily driven by the greater lengths
of stay in patients surviving ALI. However, this
cohort was collected in Washington State during
1999 to 2000 and may therefore not be able to be
generalized to hospitals outside of the northwest
United States or to contemporary patients with ALI.
Nevertheless, our conclusions remain unchanged on
varying these parameters in a sensitivity analysis.
Conclusion
Our results corroborate the findings of others that
investing in methods to implement effective care can
yield significant health benefits efficiently even when
the implementation methods are expensive.44 LPV is
cost-effective by current societal standards. Average
ICUs could invest thousands of dollars per ALI
patient to ensure that LPV is delivered, and the
combination of implementation and LPV would still
cost  $50,000 per QALY. Given the persistent low
rates of LPV delivery in the United States, scientists
should now focus on investigating the effectiveness
and eventually the cost-effectiveness of behavioral
and system-level interventions that are aimed at
improving adherence to LPV. Ventilator protocols,
increased physician or nonphysician staffing, com-
puterized ALI diagnosis and decision support, pay-
for-performance measures, and benchmarking are
all potential means to improve delivery of LPV that
warrant further study.
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